New drug cocktail shows promise for tough prostate cancer
NCT ID NCT04709276
First seen Oct 31, 2025 · Last updated Apr 26, 2026 · Updated 29 times
Summary
This study tests a mix of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in men with a rare, aggressive form of prostate cancer. The goal is to see if the combination can stop the cancer from growing for at least 6 months. Participants receive up to 10 cycles of the combo, then continue on two of the drugs as long as they help and are safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Weill Cornell Medicine
New York, New York, 10022, United States
Conditions
Explore the condition pages connected to this study.